Want to see SGHT full AI Analyst Report?
SGHT Stock Chart & Stats
$5.12
$0.21(4.28%)
At close: 4:00 PM EDT
$5.12
$0.21(4.28%)
Day’s Range― - ―
52-Week Range$3.19 - $9.24
Previous Close$5.12
Volume72.72K
Average Volume (3M)150.61K
Market Cap
$448.97M
Enterprise Value$257.64
Total Cash (Recent Filing)$79.75M
Total Debt (Recent Filing)$41.97M
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Nov 05, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding55,087,990
10 Day Avg. Volume244,568
30 Day Avg. Volume150,613
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)6.47
Price to Sales (P/S)5.35
P/FCF Ratio-13.82
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside75.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$86.13M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And GuidanceDouble-digit quarterly growth, consecutive glaucoma expansion and a raised full-year outlook indicate improving commercial execution. Sustained adoption across both segments could support a stronger revenue base over the next several quarters.
Payer Access And Product ExpansionBroader reimbursement access reduces a key adoption barrier for glaucoma procedures, while OMNI Ultra adds a cleared product to the portfolio. Together, these developments can expand addressable demand and support longer-term utilization.
Improving Operating EfficiencyHigher reported margins, lower operating expenses and sharply reduced underlying cash usage show progress toward a more efficient operating model. Although not yet profitable, better cost discipline can extend financial flexibility and move the company toward breakeven.
Bears Say
Persistent Losses And Cash BurnThe company remains materially unprofitable and cash-flow negative despite recent improvement. Continued investment in commercialization and product expansion could require additional funding if revenue growth and expense discipline do not produce sustainable breakeven.
Litigation And Royalty ExposureThe judgment creates a potentially material cash and liability burden for a company still burning cash, while royalties could reduce future economics on affected revenue. The appeal adds uncertainty rather than eliminating the underlying exposure.
Dry Eye Reimbursement UncertaintyTearCare is showing early commercial traction, but broader adoption depends on reimbursement decisions outside management's control. Delayed or limited coverage could constrain procedure volumes, slow the dry-eye ramp and reduce the diversification benefit.
Sight Sciences News
SGHT FAQ
What was Sight Sciences’s price range in the past 12 months?
Sight Sciences lowest stock price was $3.19 and its highest was $9.24 in the past 12 months.
What is Sight Sciences’s market cap?
Sight Sciences’s market cap is $448.97M.
When is Sight Sciences’s upcoming earnings report date?
Sight Sciences’s upcoming earnings report date is Nov 05, 2026 which is in 74 days.
How were Sight Sciences’s earnings last quarter?
Sight Sciences released its earnings results on Aug 05, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.183 by $0.103.
Is Sight Sciences overvalued?
According to Wall Street analysts Sight Sciences’s price is currently Undervalued.
Does Sight Sciences pay dividends?
Sight Sciences does not currently pay dividends.
What is Sight Sciences’s EPS estimate?
Sight Sciences’s EPS estimate is -0.14.
How many shares outstanding does Sight Sciences have?
Sight Sciences has 55,087,990 shares outstanding.
What happened to Sight Sciences’s price movement after its last earnings report?
Sight Sciences reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.183. Following the earnings report the stock price went up 27.748%.
Which hedge fund is a major shareholder of Sight Sciences?
Currently, no hedge funds are holding shares in SGHT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sight Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (75.78% Upside)
$9.00 (75.78% Upside)
Blogger Sentiment
Bullish
SGHT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 94.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $444.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.17%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-14.02%
Trailing 12-Months
Company Description
Sight Sciences
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.
SGHT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong operational and commercial positives — 20% total revenue growth, record Interventional Dry Eye traction, continued Interventional Glaucoma momentum, raised full-year guidance, improved operating metrics, and payer/product milestones (Aetna coverage expansion and OMNI Ultra clearance). Key risks discussed include one-time tariff refund contributions to margin, ongoing Alcon litigation and related cash/liability implications (~$55M judgment and royalties), remaining uncertainty around broader Dry Eye reimbursement timing, seasonality and tougher comps in the back half, and planned incremental investments that will increase OpEx. Overall, the company demonstrated clear progress toward growth and cash-flow improvement while acknowledging contingent risks that investors should monitor.View all SGHT earnings summariesSGHT Stock 12 Month Forecast
Average Price Target
$9.00
▲(75.78% Upside)
Technical Analysis
Ownership Overview
33.56% Insiders
5.74% Mutual Funds
13.80% Other Institutional Investors
39.26% Public Companies and
Individual Investors